ADPT sees MACD Histogram crosses below signal line ADPT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 19, 2022. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 25 instances where the indicator turned negative. In 21 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%. Technical Analysis (Indicators) Bearish Trend Analysis The 10-day RSI Indicator for ADPT moved out of overbought territory on July 11, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at . The Momentum Indicator moved below the 0 level on July 21, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on ADPT as a result. In of 53 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are . Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are . ADPT broke above its upper Bollinger Band on July 07, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. Bullish Trend Analysis The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 35 cases where ADPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are . ADPT moved above its 50-day moving average on June 23, 2022 date and that indicates a change from a downward trend to an upward trend. The 10-day moving average for ADPT crossed bullishly above the 50-day moving average on June 30, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are . Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPT advanced for three days, in of 178 cases, the price rose further within the following month. The odds of a continued upward trend are . The Aroon Indicator entered an Uptrend today. In of 140 cases where ADPT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are . The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.355) is normal, around the industry mean (25.099). P/E Ratio (0.000) is within average values for comparable stocks, (96.608). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.591). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (8.361) is also within normal values, averaging (304.383). The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents. The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock. The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents. The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average. ADPT is expected to report earnings to fall 1.80% to -43 cents per share on August 03 The last earnings report on May 04 showed earnings per share of -43 cents, beating the estimate of -45 cents. With 1.42M shares outstanding, the current market capitalization sits at 1.29B. Notable companies The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT). Industry description Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry. Market Cap The average market capitalization across the Biotechnology Industry is 1.92B. The market cap for tickers in the group ranges from 2.5K to 264.84B. NONOF holds the highest valuation in this group at 264.84B. The lowest valued company is IMUND at 2.5K. High and low price notable news The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was -21%. GOVX experienced the highest price growth at 330%, while OBSV experienced the biggest fall at -84%. Volume The average weekly volume growth across all stocks in the Biotechnology Industry was 39%. For the same stocks of the Industry, the average monthly volume growth was -92% and the average quarterly volume growth was -37% Fundamental Analysis Ratings The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows Valuation Rating: 50 a company, which engages in the development of an immune medicine platform A.I.dvisor indicates that over the last year, ADPT has been closely correlated with VCYT. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if ADPT jumps, then VCYT could also see price increases. More